Clinical trials: Transfusions
Autism Spectrum Disorder, Autism
Allogenic Cord Blood Transfusion in Patients With Autism
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic…
- Trial name
- NCT03786744
- Testing
- ASD CB-MNC injection., Standard therapy.
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Cardiopulmonary Bypass
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
We designed a prospective double-blinded randomized trial in an attempt to detect a difference between tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in reducing transfusion in patients undergoing cardiac surgery.
- Trial name
- NCT01248104
- Testing
- Tranexamic Acid, Aminocaproic Acid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loma Linda University
Preterm Infants
Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants
Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements.
- Trial name
- NCT01235923
- Testing
- three times weekly Epo, weekly Epo
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of New Mexico
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).
- Trial name
- NCT04770753
- Testing
- Mitapivat
- Where
- 68 sites in United States, Brazil and 16 more
- Volunteers
- 194 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Cardiovascular Diseases
Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death.
- Trial name
- INOBA (NCT02280655)
- Testing
- Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Emory University
Beta-Thalassemia
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or…
- Trial name
- NCT03207009
- Testing
- LentiGlobin BB305 Drug Product
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 19 people
- Sponsor
- Genetix Biotherapeutics Inc.
Thrombocytopenia, Alloimmune Platelet Refractoriness
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Background: Platelets are tiny cells in the blood that help stop bleeding. Thrombocytopenia happens when people do not have enough normal platelets.
- Trial name
- NCT02298933
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Beta-Thalassemia Major, Sickle Cell Disease
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to participants with either transfusion dependent beta-thalassemia (TDT) or sickle cell disease (SCD).
- Trial name
- NCT02151526
- Testing
- LentiGlobin BB305 Drug Product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Genetix Biotherapeutics Inc.
Sickle Cell Disease, Iron Overload
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
- Conditions
- Sickle Cell Disease, Iron Overload, Hemolytic Anemia
- Trial name
- NCT00110617
- Testing
- Deferasirox (ICL670), Deferoxamine (DFO)
- Where
- 59 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- Novartis Pharmaceuticals
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Non-transfusion Dependent Thalassemia
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
Assessed the efficacy of deferasirox in patients with non-transfusion dependent thalassemia based on change in liver iron concentration from baseline after 52 weeks of treatment.
- Trial name
- THETIS (NCT01709838)
- Testing
- deferasirox
- Where
- 11 sites in China, Greece and 6 more
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT03900715
- Testing
- Luspatercept
- Where
- 19 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Celgene
Hyperbilirubinemia, Erythroblastosis, Fetal
Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease
The use of intravenous immunoglobulin G (IVIG) therapy has been reported in hyperbilirubinemia of Rh hemolytic disease but we don't have enough evidences for it.
- Trial name
- NCT00288600
- Testing
- Intravenous Immunoglobulin, Normal saline solution
- Where
- Brazil
- Volunteers
- 92 people
- Sponsor
- Oswaldo Cruz Foundation
Focus of Study, Coagulation Status of Cardiac Surgery Patient
Thromboelastography-derived Functional Fibrinogen Levels
This study hopes to determine if thromboelastography-derived functional fibrinogen (TEG-FF or FLEV) levels obtained during the rewarming phase of cardiopulmonary bypass can provide information on coagulation status sooner…
- Conditions
- Focus of Study, Coagulation Status of Cardiac Surgery Patient, Reducing Excess Blood Transfusion
- Trial name
- TEG-FF (NCT01992757)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Pennsylvania
Myelodysplastic Syndromes
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to…
- Trial name
- NCT02598661
- Testing
- Imetelstat Sodium
- Where
- 126 sites in United States, Belgium and 15 more
- Volunteers
- 289 people
- Sponsor
- Geron Corporation
Cardiopulmonary Bypass Surgery
Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial
This study is testing whether pathogen reduced platelets can control bleeding as well as non-pathogen reduced platelets (otherwise known as large volume delayed sampling).
- Trial name
- PEDITREC (NCT05293106)
- Testing
- Platelet Transfusion
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Weill Medical College of Cornell University
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Hip Fractures
Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population
The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.
- Trial name
- TAHFT (NCT03923959)
- Testing
- Tranexamic Acid Injectable Solution
- Where
- United States
- Volunteers
- 283 people
- Sponsor
- Lancaster General Hospital
Leukemia
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk for infection.
- Trial name
- NCT01204788
- Testing
- Prophylactic White Cell Transfusion, Therapeutic White Cell Transfusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease, Hemoglobin SC
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Patients are being asked to participate in this study because they have severe sickle cell anemia (SCD) with or without the beta thalassemia trait.
- Trial name
- SCALLOP (NCT00578344)
- Testing
- Busulfan, Campath 1H, Cyclophosphamide and MESNA
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Tami D. John